{
    "nct_id": "NCT04625270",
    "official_title": "A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)",
    "inclusion_criteria": "* Histologically proven LGSOC (ovarian, peritoneal)\n* Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease.\n* Measurable disease according to RECIST 1.1\n* An Eastern Cooperative Group (ECOG) performance status ≤ 1.\n* Adequate organ function\n* Adequate recovery from toxicities related to prior treatments\n* Agreement to use highly effective method of contraceptive, if necessary\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy\n* Co-existing high-grade ovarian cancer or another histology\n* History of prior malignancy with recurrence <3 years from the time of enrollment\n* Major surgery within 4 weeks\n* Symptomatic brain metastases requiring steroids or other interventions\n* Known SARS-Cov2 infection (clinical symptoms) ≤28 days prior to first dose of study therapy\n* For subjects with prior MEK exposure, Grade 4 toxicity deemed related to the MEK inhibitor\n* Active skin disorder that has required systemic therapy within the past year\n* History of rhabdomyolysis\n* Concurrent ocular disorders\n* Concurrent heart disease or severe obstructive pulmonary disease\n* Subjects with the inability to swallow oral medications",
    "miscellaneous_criteria": ""
}